Validation of Respiration Rate Algorithms

NCT ID: NCT01472133

Last Updated: 2014-02-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Continuous accurate unobtrusive respiratory rate monitoring may lead to improved patient outcomes, as respiratory rate is thought to be a sensitive marker of patient deterioration. Currently systems are not suitable for long term monitoring, particularly in ambulant patients as they are too restrictive. To ensure that our algorithms are suitable for use in a clinical context we need to demonstrate their performance not only in the optimal situation, healthy volunteers at rest, but also in more challenging situations such as where the person being monitored is moving and also in patients who have conditions which may affect their physiology in such a way that the accuracy of the respiration rate estimation may be affected.

No previous study has systematically tested algorithms deriving respiratory rate from either the ECG or the photoplethysmography (PPG) waveforms in a real -world setting.

The algorithms work by looking for changes in intervals between heartbeats and also changes in the sizes of the ECG and PPG waveforms, both of which may be caused by respiration. These changes tend to diminish with increasing age and also conditions which alter the chest movement and cardiac reflexes. Thus it is important to test our algorithms' accuracy in participants exhibiting these conditions. It is also important to ensure that the calculations of respiratory rate are accurate across a range of heart rates and respiratory rates. Our testing covers all these variables.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Rate Pulse Oximetry

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Young Healthy Volunteers

Healthy volunteers under the age of 40

Recording of 12 lead ECG

Intervention Type OTHER

Recording of 12 lead ECG

Recording of lying and standing blood pressure

Intervention Type OTHER

Recording of lying and standing blood pressure

Recording of chest wall movement

Intervention Type OTHER

Recording of chest wall movement

Recording of heart rate variability

Intervention Type OTHER

Done during deep breathing and a valsalva manoeuvre

Recording of ECG and Pulse oximeter waveform at rest

Intervention Type OTHER

For 10 mins

Recording of ECG and Pulse oximeter waveform during exercise

Intervention Type OTHER

Recording of ECG and Pulse oximeter waveform during exercise

Older healthy volunteers

Healthy volunteers over the age of 70

Recording of 12 lead ECG

Intervention Type OTHER

Recording of 12 lead ECG

Recording of lying and standing blood pressure

Intervention Type OTHER

Recording of lying and standing blood pressure

Recording of chest wall movement

Intervention Type OTHER

Recording of chest wall movement

Recording of heart rate variability

Intervention Type OTHER

Done during deep breathing and a valsalva manoeuvre

Recording of ECG and Pulse oximeter waveform at rest

Intervention Type OTHER

For 10 mins

Patients with atrial fibrillation

Patients with permanent AF

Recording of 12 lead ECG

Intervention Type OTHER

Recording of 12 lead ECG

Recording of lying and standing blood pressure

Intervention Type OTHER

Recording of lying and standing blood pressure

Recording of chest wall movement

Intervention Type OTHER

Recording of chest wall movement

Recording of heart rate variability

Intervention Type OTHER

Done during deep breathing and a valsalva manoeuvre

Recording of ECG and Pulse oximeter waveform at rest

Intervention Type OTHER

For 10 mins

Patients with a pacemaker

Patients who have an implanted pacemaker that is continually pacing

Recording of 12 lead ECG

Intervention Type OTHER

Recording of 12 lead ECG

Recording of lying and standing blood pressure

Intervention Type OTHER

Recording of lying and standing blood pressure

Recording of chest wall movement

Intervention Type OTHER

Recording of chest wall movement

Recording of heart rate variability

Intervention Type OTHER

Done during deep breathing and a valsalva manoeuvre

Recording of ECG and Pulse oximeter waveform at rest

Intervention Type OTHER

For 10 mins

Patients with restricted chest movement

Patients whose chest expansion is less than 2.5cm

Recording of 12 lead ECG

Intervention Type OTHER

Recording of 12 lead ECG

Recording of lying and standing blood pressure

Intervention Type OTHER

Recording of lying and standing blood pressure

Recording of heart rate variability

Intervention Type OTHER

Done during deep breathing and a valsalva manoeuvre

Recording of ECG and Pulse oximeter waveform at rest

Intervention Type OTHER

For 10 mins

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recording of 12 lead ECG

Recording of 12 lead ECG

Intervention Type OTHER

Recording of lying and standing blood pressure

Recording of lying and standing blood pressure

Intervention Type OTHER

Recording of chest wall movement

Recording of chest wall movement

Intervention Type OTHER

Recording of heart rate variability

Done during deep breathing and a valsalva manoeuvre

Intervention Type OTHER

Recording of ECG and Pulse oximeter waveform at rest

For 10 mins

Intervention Type OTHER

Recording of ECG and Pulse oximeter waveform during exercise

Recording of ECG and Pulse oximeter waveform during exercise

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Young Healthy Volunteers

* Participant is willing and able to give informed consent for participation in the study.
* Male or Female, aged between 18 and 40 years old.
* Older Healthy Volunteers

* Participant is willing and able to give informed consent for participation in the study.
* Male or Female, aged 70 years or above.
* Patients

* Participant is willing and able to give informed consent for participation in the study.
* Male or Female, aged 18-70 years old.
* Participant has one of the following conditions:
* Atrial fibrillation
* A permanent pacemaker that is continuously active
* Reduced chest wall movement

* Inability to give informed consent

Exclusion Criteria

* Young Healthy Volunteers

* Any condition which might increase the risk of exercise testing
* Any history of ischaemic heart disease
* Any history of heart failure
* Any structural heart disease (eg: valvular lesions, hypertrophic obstructive cardiomyopathy)
* Any abnormalities on a resting ECG
* Deep vein thrombosis diagnosed within the last 6 months or under active treatment
* Uncontrolled hypertension (systolic blood pressure \>220 mm Hg, diastolic \>120 mm Hg)
* Aortic aneurysm
* Aortic or cardiovascular surgery within 6 months of recruitment
* A family history of sudden cardiac death, congenital arrhythmia syndromes or cardiomyopathy
* Autonomic dysfunction, either previously diagnosed or upon testing by the research team
* Any condition involving the brain or spinal cord
* Diabetes
* Alcohol consumption \> 21 units/week for women and 28 units/week for men or a history of previous alcohol dependence.
* Acute kidney injury
* Chronic kidney disease stage 4 or 5
* Any condition causing hepatic dysfunction
* Presence of a permanent pacemaker (these participants would be eligible for the pacemaker group)
* Reduced chest wall movement (these participants would be eligible for the reduced chest movement group)
* Any acute infection requiring antibiotic treatment within 3 months of recruitment
* Any other surgery or illness requiring hospitalisation within 3 months of recruitment
* Currently taking any medication with the exception of analgesics or the oral contraceptive pill.
* Any wound or skin condition affecting the torso which may be affected by the application of adhesive ECG dots to the skin
* Pregnancy
* Inability to give informed consent
* Older Healthy Volunteers

* Any diagnosed condition primarily affecting the cardiovascular or respiratory systems
* Symptomatic autonomic dysfunction
* Orthostatic hypotension
* Any condition involving the brain or spinal cord
* Diabetes
* Alcohol consumption \> 21 units/week for women and 28 units/week for men or a history of previous alcohol dependence.
* Acute kidney injury
* Chronic kidney disease stage 4 or 5
* Any condition causing hepatic dysfunction
* Presence of a permanent pacemaker
* Chronic Obstructive Pulmonary Disease (COPD).
* Any muscular dystrophy
* Kyphosis
* Scoliosis
* Pectus excavatum
* Any disease involving the lungs or pleura
* Any acute infection requiring antibiotic treatment within 3 months of recruitment
* Any other surgery or illness requiring hospitalisation within 3 months of recruitment
* Currently taking any medication with the exception of analgesics or the oral contraceptive pill.
* Any wound or skin condition affecting the torso which may be affected by the application of adhesive ECG dots to the skin
* Pregnancy
* Inability to give informed consent
* Patients

* Any infection which would require isolation or barrier nursing according to the hospital's infection control policy
* Any wound or skin condition affecting the torso which may be affected by the application of adhesive ECG dots to the skin
* Requirement for any form of artificial ventilatory support, including oxygen therapy
Minimum Eligible Age

18 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Engineering and Physical Sciences Research Council, UK

OTHER

Sponsor Role collaborator

University of Oxford

OTHER

Sponsor Role collaborator

Guy's and St Thomas' NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Richard Beale

Clinical Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard Beale, MBBS, FRCA

Role: PRINCIPAL_INVESTIGATOR

Guy's and St Thomas' Foundation Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St Thomas' Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11/LO/1667

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The PneumoRator Study
NCT07293299 RECRUITING
Pulse Oximeter Motion Study
NCT03156140 COMPLETED NA